

Special Issue

Novel Insights in Acute Lymphoblastic and Myeloblastic Leukemia

Message from the Guest Editor

Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are bone marrow and blood cancers with abnormal populations of lymphocytes and myeloblasts, respectively, although both can induce complications at the central nervous system level. ALL and AML are heterogenous diseases; genetic and epigenetic alterations in cell progenitors cause a dysregulation of multiple and diverse signal transduction pathways. Therefore, we are pleased to invite researchers to contribute to this Special Issue which intends to address the need to find more new drug-able targets than can reach the heterogeneity of leukemic patients. Manuscripts that accommodate omics technologies and their integration, which explore previously published datasets and/or bioinformatics and artificial intelligence strategies to find out common or alternative drug-able routes, are also of interest in this Issue. Provocative insights from past and current research to consider new drug-able features will be appreciated. In this Special Issue, original research articles, short communications, opinions, and reviews are welcome.

Guest Editor

Dr. María Hernández Valladares
Department of Physical Chemistry, University of Granada, Granada,
Spain

Deadline for manuscript submissions

closed (29 February 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/142288

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)